Annotation Detail
Information
- Associated Genes
- PDGFRB
- Associated Variants
- PDGFRB PDGFRB FUSIONS PDGFRB PDGFRB FUSIONS
- Associated Disease
- myeloproliferative neoplasm
- Source Database
- CIViC Evidence
- Description
- Twelve patients with BCR-ABL-negative chronic myeloproliferative disease and reciprocal translocations involving PDGFRB received imatinib for a median of 47 months (range, 0.1-60 months). Eleven had prompt responses, 10 had complete resolution of cytogenetic abnormalities and decrease or disappearance of fusion transcripts as measured by reverse transcriptase-polymerase chain reaction (RT-PCR). Updates were sought from 8 further patients previously described in the literature; prompt responses were described in 7 and persist in 6.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1498
- Gene URL
- https://civic.genome.wustl.edu/links/genes/4176
- Variant URL
- https://civic.genome.wustl.edu/links/variants/568
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Chronic Myeloproliferative Disease
- Evidence Direction
- Supports
- Drug
- Imatinib
- Evidence Level
- A
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 16960151
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Imatinib | Sensitivity | true |